Latest Asx Company Filings News

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

AVADA Group Limited reported a significant net loss of $17.6 million for FY25, driven by major impairments in New Zealand and New South Wales operations amid challenging market conditions. The company completed a strategic consolidation of its Australian businesses and appointed new senior management to steer operational transformation.

Australian Agricultural Projects Limited reported a $1.96 million profit for FY2025, driven by a strong olive oil harvest despite frost setbacks and rising olive oil prices. The company plans to farm a key orchard section directly after leaseholders declined renewal.

RBR Group Limited reported an 88% plunge in revenue and a widening net loss for FY2025, impacted by political instability and LNG project delays in Mozambique. The company is investing in facility upgrades and workforce training to position itself for a market rebound.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.

Motio Limited has reported a remarkable financial turnaround for the year ended June 30, 2025, with profit after tax more than doubling and Cash EBITDA soaring by 291%. Despite these gains, the company has opted not to declare a dividend.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Waterco Limited reported a 4% increase in FY25 sales revenue to $249.4 million, driven by regional growth and integration benefits from the Davey acquisition. Despite revenue gains, earnings declined due to cost pressures and restructuring, with statutory NPAT down 31%.

Waterco Limited reported a modest 4% revenue increase for FY25 but saw net profit fall sharply by 31%, weighed down by restructuring and foreign exchange losses. The company maintains its dividend and eyes growth through innovation and regional expansion.